Paul Tappenden

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 17

Top Topics

Systematic Review

Top Venues

PharmacoEconomics

Health technology assessment (Winchester, England)

International journal of technology assessment in health care

British journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Paul Tappenden, Orla Hardiman, Sun-Hong Kwon, Mon Mon-Yee, Miriam Galvin, Christopher J McDermott, null null
A Model-Based Economic Evaluation of Hypothetical Treatments for Amyotrophic Lateral Sclerosis in the UK: Implications for Pricing of New and Emerging Health Technologies. PharmacoEconomics 42 (9) (2024)
Johanna Lister, Suzy Paisley, Christopher Carroll, Paul Tappenden
Empirical Testing of Alternative Search Methods to Retrieve Utility Values for Health Economic Modelling. PharmacoEconomics (2024)
Paul Tappenden, Orla Hardiman, Sun-Hong Kwon, Mon Mon-Yee, Miriam Galvin, Christopher J McDermott, null null
A Model-Based Economic Evaluation of Hypothetical Treatments for Amyotrophic Lateral Sclerosis in the UK: Implications for Pricing of New and Emerging Health Technologies. PharmacoEconomics (2024)
Paul Tappenden, Aline Navega Biz, Mónica Hernández Alava, Alessandro Sasso, Laura Sutton, Kate Ennis, Rachel Elliott, Martin Wildman
A model-based economic analysis of the CFHealthHub intervention to support adherence to inhaled medications for people with cystic fibrosis in the UK. International journal of technology assessment in health care 39 (1) (2023)
Paul Tappenden, Aline Navega Biz, Mónica Hernández Alava, Alessandro Sasso, Laura Sutton, Kate Ennis, Rachel Elliott, Martin Wildman
A model-based economic analysis of the CFHealthHub intervention to support adherence to inhaled medications for people with cystic fibrosis in the UK. International journal of technology assessment in health care 39 (1) (2023)
Peter Murphy, David Glynn, Sofia Dias, Robert Hodgson, Lindsay Claxton, Lucy Beresford, Katy Cooper, Paul Tappenden, Kate Ennis, Alessandro Grosso, Kath Wright, Anna Cantrell, Matthew D Stevenson, Stephen Palmer
Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework. Health technology assessment (Winchester, England) 25 (76) (2022)
Huajie Jin, Paul Tappenden, Stewart Robinson, Evanthia Achilla, James Hunter MacCabe, David Aceituno, Sarah Byford
A Systematic Review of Economic Models Across the Entire Schizophrenia Pathway. PharmacoEconomics 38 (6) (2021)
Tushar Srivastava, Nicholas R Latimer, Paul Tappenden
Estimation of Transition Probabilities for State-Transition Models: A Review of NICE Appraisals. PharmacoEconomics 39 (8) (2021)
Paul Tappenden, Emma Simpson, Jean Hamilton, Daniel Pollard, Mark Clowes, Eva Kaltenthaler, David Meiklejohn, Nick Morley
Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics 37 (3) (2020)
Paul Tappenden, Christopher Carroll, Jean Hamilton, Eva Kaltenthaler, Ruth Wong, Jonathan Wadsley, Laura Moss, Sabapathy P Balasubramanian
Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model. Health technology assessment (Winchester, England) 23 (8) (2020)
Paul Tappenden, Christopher Carroll, John Stevens, Emma Simpson, Praveen Thokala, Ruth Wong, Josh Wright, Rebecca Auer
Ibrutinib for Treating Waldenström's Macroglobulinaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics 37 (1) (2020)
Katy Cooper, Paul Tappenden, Anna Cantrell, Kate Ennis
A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer. British journal of cancer 123 (11) (2020)
S E Harnan, Paul Tappenden, Katy Cooper, John W Stevens, Alice Bessey, Rachid Rafia, Sue E Ward, Ruth Wong, Robert C Stein, Janet Brown
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis. Health technology assessment (Winchester, England) 23 (30) (2020)
Inigo Bermejo, Paul Tappenden, Ji-Hee Youn
Response to 'Comment on "Replicating Health Economic Models: Firm Foundations or a House of Cards?"'. PharmacoEconomics 35 (11) (2019)
Paul Tappenden, Susannah Sadler, Martin Wildman
An Early Health Economic Analysis of the Potential Cost Effectiveness of an Adherence Intervention to Improve Outcomes for Patients with Cystic Fibrosis. PharmacoEconomics 35 (6) (2018)
Paul Tappenden, Christopher Carroll, John W Stevens, Andrew Rawdin, Sabine Grimm, Mark Clowes, Eva Kaltenthaler, John R Ingram, Fiona Collier, Mohammad Ghazavi
Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics 35 (8) (2018)
Paul Tappenden, Sue Harnan, Shijie Ren, Praveen Thokala, Ruth Wong, Clara Mukuria, Clare Green, Simon Pledge, John Tidy
Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics 35 (1) (2017)